Kymab: Biotech Company that is ‘One to Watch’
News Sep 15, 2015
Kymab, the Cambridge-based antibodies-to-medicines company, is featured in the top ten of The Sunday Times Tech Track ‘Ones to Watch’ 2015 list.
The ranking recognises Kymab’s potential for rapid future sales growth and increasing international presence. The Sunday Times Hiscox Tech Track 100 ranks Britain’s 100 fastest growing private companies, based on sales over three years.
With investment from Bill & Melinda Gates Foundation, Malin Corporation plc, the Wellcome Trust, and Woodford Patient Capital Trust plc, Kymab is using its unique antibody development platform in therapeutic development and vaccine discovery. Its current targets include autoimmune disease and cancers, as well as infectious disease, such as HIV and malaria.
“I am delighted and very proud that the growth Kymab has made has been recognised by The Sunday Times Tech Track, a barometer for success,” says Professor Allan Bradley, Chief Technical Officer, who founded Kymab in 2009. “The healthcare and research partners we work with know that Kymab is achieving remarkable results; our investors know that we are performing extremely well.”
Dr. David Chiswell Chairman and interim CEO added: “To be recognised for our business performance by inclusion in this highly regarded table is a significant achievement for our Company.”
The recognition follows Kymab’s nomination in June 2015 for the Emerging Star award at the London Stock Exchange techMARK mediscience annual event which celebrates excellence within the life-sciences sector.
Therapeutic Avenue for Parkinson's Disease?News
A new potential therapeutic avenue for Parkinson's disease. This research is unusual given that it focuses on senescence in astrocytes, so called "helper" cells that perform a variety of tasks, from axon guidance and synaptic support to control of the blood brain barrier and blood flow.READ MORE
Cobra Biologics Awarded £2.6m ($3.4m USD) from Innovate UKNews
Capital infrastructure investment to embed and secure clinical and commercial viral vector manufacturing capability within the UK. Award made as part of UK’s Innovation Agency’s Industrial Strategy boost for UK medicines with £70m of funding to help develop new treatments.READ MORE
‘Long Acting’ Nanomedicine for the Prevention Of MalariaNews
A new study, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new 'long acting' medicine for the prevention of malaria.READ MORE